No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study

Clinical and Experimental Rheumatology

Volumn 21, Issue 3, 2003, Pages 359-362

  van der Laan, Willemijn H ^a,b,d   Ronday, H Karel ^c   TeKoppele, Johan M ^a   Breedveld, Ferdinand C ^b   Huizinga, Tom W J ^b   Verheijen, Jan H ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Joint destruction; Plasmin; Pyridinolines; Rheumatoid arthritis; Tranexamic acid

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; MOLECULAR MARKER; PREDNISOLONE; PYRIDINOLINE; SALAZOSULFAPYRIDINE; TRANEXAMIC ACID;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; ARTICULAR CARTILAGE; BONE DEFECT; CARTILAGE DEGENERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; JOINT DESTRUCTION; MALE; MEDICAL ASSESSMENT; MEDICAL PARAMETERS; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; URINARY EXCRETION;

AMINO ACIDS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PAIN MEASUREMENT; PILOT PROJECTS; PLASMIN; PROBABILITY; RANGE OF MOTION, ARTICULAR; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 0037534395     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. HARRIS E: Etiology and pathogenesis of rheumatoid arthritis. In KELLEY WN, HARRIS ED, RUDDY S, and SLEDGE CB (Eds.): Textbook of Rheumatology, 4th ed. Philadelphia, W.B. Saunders Co. 1993; 833-73.
2. WERB Z, MAINARDI CL, VATER CA, HARRIS ED JR: Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977; 296: 1017-23.
3. DEL ROSSO M, FIBBI G, MATUCCI CERINIC M: The urokinase-type plasminogen activator system and inflammatory joint diseases. Clin Exp Rheumatol 1999; 17: 485-98.
4. RONDAY HK, SMITS HH, VAN MUIJEN GN et al.: Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996; 35: 416-23.
5. BUSSO N, PECLAT V, SO A, SAPPINO AP: Plasminogen activation in synovial tissues: Differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997; 56: 550-7.
6. VAN DER LAAN WH, PAP T, RONDAY HK et al.: Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthritis Rheum 2000; 43:1710-8.
7. SAITO S, KATOH M, MASUMOTO M, MATSUMOTO S, MASUHO Y: Collagen degradation induced by the combination of IL- 1alpha and plasminogen in rabbit articular cartilage explant culture. J Biochem (Tokyo) 1997; 122: 49-54.
8. RONDAY HK, SMITS HH, QUAX PH et al.: Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997; 36: 9-15.
9. AHLBERG A, ERIKSSON O, KJELLMAN H: Diffusion of tranexamic acid to the joint. Acta Orthop Scand 1976; 47: 486-8.
10. PILBRANT A, SCHANNONG M, VESSMAN J: Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981; 20: 65-72.
11. BUTLER M, COLOMBO C, HICKMAN L et al.: A new model of osteoarthritis in rabbits. III. Evaluation of anti -osteoarthritic effects of selected drugs administered intraarticularly. Arthritis Rheum 1983; 26: 1380-6.
12. VIGNON E, MATHIEU P, BEJUI J et al.: Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis. J Rheumatol 1991; 27 (Suppl.): 131-3.
13. RONDAY HK, TE KOPPELE JM, GREENWALD RA et al.: Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. Br J Rheumatol 1998; 37: 34-8.
14. VERHOEVEN AC, BOERS M, TE KOPPELE JM et al.: Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. Rheumatology (Oxford) 2001; 11: 1231-7.
15. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LBA, VAN RIEL PLCM: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
17. BANK RA, BEEKMAN B, VERZIJL N, DE ROOS JADM, SAKKEE AN, TeKOPPELE JM: Sensitive fluorimetric quantitation of pyridinium and pentosidine crosslinks in biological samples in a single high-performance liquid chromatographic run. J Chromatogr B Biomed Sci Appl 1997; 703: 37-44.
18. RASMUSSEN GG, BRANDSLUND I, URFE P et al.: Lack of effect of tranexamic acid on rheumatoid arthritis. Scand J Rheumatol 1984; 13: 369-73.